Compugen (CGEN) - Total Assets
Based on the latest financial reports, Compugen (CGEN) holds total assets worth ILA137.31 Million ILA (≈ $368.12K USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Compugen - Total Assets Trend (1999–2025)
This chart illustrates how Compugen's total assets have evolved over time, based on quarterly financial data. Also see Compugen (CGEN) market capitalisation for the company's overall valuation and market capitalisation.
Compugen - Asset Composition Analysis
Current Asset Composition (December 2025)
Compugen's total assets of ILA137.31 Million consist of 94.4% current assets and 5.6% non-current assets. Review CGEN current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (ILA) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 57.8% |
| Accounts Receivable | ILA294.00K | 0.2% |
| Inventory | ILA0.00 | 0.0% |
| Property, Plant & Equipment | ILA0.00 | 0.0% |
| Intangible Assets | ILA0.00 | 0.0% |
| Goodwill | ILA0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Compugen's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Compugen share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Compugen's current assets represent 94.4% of total assets in 2025, an increase from 80.7% in 1999.
- Cash Position: Cash and equivalents constituted 57.8% of total assets in 2025, down from 73.7% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Compugen Competitors by Total Assets
Key competitors of Compugen based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Compugen - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.72 | 4.74 | 7.36 |
| Quick Ratio | 5.72 | 4.74 | 7.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ILA105.96 Million | ILA77.06 Million | ILA97.03 Million |
Compugen - Advanced Valuation Insights
This section examines the relationship between Compugen's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.43 |
| Latest Market Cap to Assets Ratio | 1.19 |
| Asset Growth Rate (YoY) | 36.4% |
| Total Assets | ILA156.87 Million |
| Market Capitalization | $186.23 Million USD |
Valuation Analysis
Above Book Valuation: The market values Compugen's assets above their book value (1.19x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Compugen's assets grew by 36.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Compugen (1999–2025)
The table below shows the annual total assets of Compugen from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ILA156.87 Million ≈ $420.57K |
+36.42% |
| 2024-12-31 | ILA115.00 Million ≈ $308.30K |
-5.22% |
| 2023-12-31 | ILA121.33 Million ≈ $325.29K |
+28.84% |
| 2022-12-31 | ILA94.18 Million ≈ $252.48K |
-28.74% |
| 2021-12-31 | ILA132.16 Million ≈ $354.32K |
-4.45% |
| 2020-12-31 | ILA138.32 Million ≈ $370.82K |
+157.27% |
| 2019-12-31 | ILA53.76 Million ≈ $144.14K |
+1.10% |
| 2018-12-31 | ILA53.18 Million ≈ $142.57K |
+37.25% |
| 2017-12-31 | ILA38.75 Million ≈ $103.88K |
-45.53% |
| 2016-12-31 | ILA71.14 Million ≈ $190.72K |
-28.36% |
| 2015-12-31 | ILA99.31 Million ≈ $266.24K |
-13.53% |
| 2014-12-31 | ILA114.84 Million ≈ $307.90K |
+102.51% |
| 2013-12-31 | ILA56.71 Million ≈ $152.04K |
+96.17% |
| 2012-12-31 | ILA28.91 Million ≈ $77.50K |
-0.59% |
| 2011-12-31 | ILA29.08 Million ≈ $77.97K |
-20.23% |
| 2010-12-31 | ILA36.46 Million ≈ $97.74K |
+20.78% |
| 2009-12-31 | ILA30.18 Million ≈ $80.92K |
+111.91% |
| 2008-12-31 | ILA14.24 Million ≈ $38.19K |
-34.26% |
| 2007-12-31 | ILA21.67 Million ≈ $58.09K |
-29.78% |
| 2006-12-31 | ILA30.86 Million ≈ $82.72K |
-26.72% |
| 2005-12-31 | ILA42.11 Million ≈ $112.88K |
-23.93% |
| 2004-12-31 | ILA55.35 Million ≈ $148.40K |
-18.03% |
| 2003-12-31 | ILA67.53 Million ≈ $181.03K |
-12.60% |
| 2002-12-31 | ILA77.26 Million ≈ $207.12K |
-11.49% |
| 2001-12-31 | ILA87.29 Million ≈ $234.02K |
-10.81% |
| 2000-12-31 | ILA97.87 Million ≈ $262.39K |
+530.70% |
| 1999-12-31 | ILA15.52 Million ≈ $41.60K |
-- |
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more